This article is more than 5 years old. Information may no longer be current.
Analysis: Lucentis and Eylea comparable in injection frequency, cost in AMD patients at 2 years
Click Here to Manage Email Alerts
SEATTLE — Ranibizumab and aflibercept were shown to be comparable in injection frequency and cost for the treatment of patients with neovascular age-related macular degeneration at 2 years, according to a poster presented here.
“In terms of the real-world use of aflibercept and ranibizumab, there seems to be no difference whether the patient is treatment naïve or treatment experienced, and that’s true at 1 year and at 2 years,” Szilárd Kiss, MD, told Ocular Surgery News in an interview at the Association for Research in Vision and Ophthalmology meeting.
Szilárd Kiss
The 2-year claims-based analysis included 1,018 treatment-naïve patients who received Lucentis (ranibizumab, Genentech), 482 treatment-naïve patients who received Eylea (aflibercept, Regeneron), 344 previously treated patients who received Lucentis, and 847 previously treated patients who received Eylea.
At 2 years, mean injection frequency in treatment-naïve patients was 7.6 for those receiving ranibizumab and 8 for those receiving aflibercept. Mean cost for treatment-naïve patients was $15,467 for those who received ranibizumab and $15,186 for those who received aflibercept.
Mean injection frequency in previously treated patients was 9.1 for those receiving ranibizumab and 9.4 for those receiving aflibercept. Mean cost for previously treated patients was $18,179 for those who received ranibizumab and $18,906 for those who received aflibercept.
“In macular degeneration, this particular analysis continues to show what has been shown previously, which is that we are undertreating compared to large randomized clinical trials both at 1 year and at 2 years,” Kiss said. – by Nhu Te
Reference:
Kiss S, et al. Real-world treatment patterns in injection cost and frequency for ranibizumab versus aflibercept in patients with wet age-related macular degeneration: A 2-year U.S. claims analysis. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-5, 2016; Seattle.
Disclosure: Kiss reports he is a consultant for Alcon, Alimera Sciences, Allergan, Avalanche, Bausch + Lomb, Genentech/Roche and Regeneron.